Managing lines of therapy in castration-resistant prostate cancer: real-life snapshot from a multicenter cohort.
Maria Consiglia FerrieroRiccardo MastroianniCosimo De NunzioLuca CindoloFabio CalabròGiorgia TemaCostantino LeonardoRocco Simone FlammiaGabriele TudertiUmberto AnceschiAldo BrassettiSilvana GiacintiSalvatore GuaglianoneJamil GhahhariLuigi SchipsAndrea TubaroMichele GallucciGiuseppe SimonePublished in: World journal of urology (2019)
Toxicity profile, PSA response rate and oncological outcomes were comparable between first-line and second-line courses in patients treated with either AA or EZ for mCRPC. Our findings showed the tolerability and oncological effectiveness, when feasible, of two lines of therapy other than chemotherapy.
Keyphrases